Pharmaron Q3: Net Profit +42.5% and New Orders Accelerating from 10% to 13% — the Profit Elasticity Is Still Coming

Pharmaron's Q3 2026 report (published late October): third-quarter revenue of RMB 3.645B, up 13.4%, and net profit of RMB 440M, up 42.5% but slightly below consensus of RMB 467M. The more important signal sits in the order book: nine-month new-order growth of about 13%, accelerating from roughly 10% in the first half. UBS raised its H-share target price to HK$32.9 on the back of it, keeping Buy — a textbook recovery report in which orders lead and margins follow.

In the same reporting week that WuXi AppTec grabbed headlines with 136% single-quarter profit growth, Pharmaron's Q3 offered a different but equally instructive sample: a Chinese CXO in the second revenue tier, with laboratory services as its base, moving through the standard recovery sequence — orders recover first, profits convert later.

The numbers first. Third-quarter revenue was RMB 3.645B, up 13.4%, broadly in line with market and UBS forecasts of RMB 3.6–3.7B; net profit attributable to shareholders was RMB 440M, up 42.5% — more than three times the revenue growth rate, but below the market's RMB 467M and UBS's RMB 506M. On Eastmoney's figures, nine-month revenue totalled about RMB 11.24B with net profit of roughly RMB 1.19B, and the quarterly profit repair through 2026 is clearly visible.

The most important number is not on the income statement — it is in the order book

The point UBS emphasised most: Pharmaron's new orders for the first nine months grew about 13% year on year, faster than roughly 10% in the first half. The weight of that figure comes from CXO economics — new signings are the leading indicator of revenue, and the acceleration matters more than the absolute level for locating where in the cycle the industry sits.

Put the same tier of companies on one chart and the trend sharpens: WuXi AppTec's backlog of RMB 76.74B (+36.4%) with two guidance raises this year; Asymchem's new signings in double digits for the nine months and about +30% in Q3 off a high base; Pharmaron accelerating from +10% to +13%. The disclosure bases differ, but the direction is identical — the order curves of China's CXO leaders steepened together in the second half of 2026. That dovetails with the NDRC disclosure that innovative-drug out-licensing reached about USD 130B in the first three quarters, near the full-year 2025 total: BD activity is converting into outsourcing orders down the R&D chain.

Why profits lag: a recovery pace dictated by structure

Pharmaron's profit elasticity trails WuXi's not because of demand but because of mix. First, laboratory services (lab chemistry-led) dominate revenue; these are lower-priced, headcount-driven lines where revenue recovers before profit, and earnings elasticity arrives only as CDMO and late-stage large projects gain share. Second, the RMB 440M profit print still undershot consensus, so gross-margin repair, currency and new-capacity ramp costs are still being digested. Third, compared with WuXi's integrated CRDMO funnel, Pharmaron's lab-services-to-CMC-to-CDMO conversion is only now approaching its volume phase — which is why UBS's modest upward revisions to 2026–27 revenue and profit rest on improving order-to-revenue conversion.

That makes this a textbook expectations-management sample: the market holds every CXO to WuXi's growth rate, but each company's recovery curve has a different shape. WuXi is converting orders and profits in step; Pharmaron is orders first, margins second — which implies that if order growth holds, 2027 profit elasticity should exceed 2026's. That is the core logic behind UBS lifting its H-share target from HK$31 to HK$32.9 and keeping Buy.

Editorial note: one recovery, different coordinates

Over the past two weeks we have treated the Q3 season as an industry observation band: Asymchem (Q3 net +81.49%, full-year guidance 19–22%), Jiuzhou Pharmaceutical (first quarter of the year with revenue and profit both positive), Apeloa (still bottoming, though CDMO +41% in the quarter), Samsung Biologics (revenue +18.5% but margins down), and now WuXi AppTec and Pharmaron. Stack the six reports and the evidence for an inflection is close to complete — but the layering inside the inflection is equally clear: the larger a company's exposure to new modalities (TIDES, ADCs, oligonucleotides), the earlier and stronger the order and profit conversion; companies weighted to traditional small molecules and lab services recover a beat later.

For industry observers, the most useful inference of the season is this: to judge a CXO's next move, read the shape of its order book first, then its position on the new-modality map. Pharmaron's accelerating new orders say it is still in the improvement channel on both coordinates — profit elasticity is on the way, which is exactly the reporting posture of a company in mid-recovery.